Not yet recruiting
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07843303· Phase 2· Peking University Cancer Hospital & Institute· Source
Not yet recruiting
Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases
NCT07815288· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Kun Wang
Recruiting
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
NCT07622706· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Jia Wang
Not yet recruiting
Development and Validation of a Colorectal Cancer Diagnostic Model
NCT07692555· Peking University Cancer Hospital & Institute· Source
Contact: Zhonghu He, PhD
Active, not recruiting
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
NCT07745322· Peking University Cancer Hospital & Institute· Source
Not yet recruiting
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
NCT07357532· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Jun Zhao
Recruiting
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
NCT07413042· Phase 1· Peking University Cancer Hospital & Institute· Source
Contact: Zhi Yang
Active, not recruiting
Retrospective Analysis of a Psoralea Corylifolia (Buguzhi)-Containing TCM Formula for Gastrointestinal Cancers
NCT07932951· Peking University Cancer Hospital & Institute· Source
Recruiting
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07262567· Phase 3· Genfleet Therapeutics (Shanghai) Inc.· Source
Contact: Lin Shen
Not yet recruiting
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
NCT07007728· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Kun Wang
Recruiting
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
NCT06969612· Phase 1· Peking University Cancer Hospital & Institute· Source
Contact: Minglei Zhuo
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223· Phase 1/2· Peking University Cancer Hospital & Institute· Source
Contact: Minglei Zhuo
Recruiting
ctDNA-MRD Monitoring After Resection in Gastric Cancer
NCT06893133· Peking University· Source
Contact: Yongning Jia Associate Chief Physician, Dr.
Recruiting
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
NCT06849167· Phase 2· Peking University Cancer Hospital & Institute· Source
Contact: Teng
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
NCT06869239· Peking University Cancer Hospital & Institute· Source
Contact: Anhui Shi
Recruiting
Phase I Study of OriC902 in Treatment of Advanced HCC
NCT06891742· Phase 1· Peking University· Source
Contact: Changsong Qi
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
NCT06926179· Peking University Cancer Hospital & Institute· Source
Contact: Nan Wu, MD
Recruiting
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
NCT06648317· Peking University Cancer Hospital & Institute· Source
Contact: Nan Li, MD
Recruiting
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
NCT06732505· Phase 1· Peking University Cancer Hospital & Institute· Source
Contact: Yang
Recruiting
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06341335· Phase 3· Akeso· Source
Contact: Lin Shen, MD
Not yet recruiting
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
NCT06443671· Phase 2/3· Peking University Cancer Hospital & Institute· Source
Contact: Xiao Kang Lei, M.D.
Active, not recruiting
Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal Adenocarcinoma
NCT04556253· Phase 2· Peking University· Source
Recruiting
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
NCT06209099· Peking University Cancer Hospital & Institute· Source
Contact: Lin Wang, M.D.
Active, not recruiting
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860· Phase 1/2· Beijing Scitech-Mq Pharmaceuticals Limited· Source
Recruiting
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250· Chinese Academy of Sciences· Source
Contact: Lei Tang
Active, not recruiting
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427· Peking University Cancer Hospital & Institute· Source
Active, not recruiting
Study of ST-1898 in Advanced Renal Cell Carcinoma
NCT06127238· Phase 1/2· Beijing Scitech-Mq Pharmaceuticals Limited· Source
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275· Chinese Academy of Sciences· Source
Contact: Lei Tang